Cargando…
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of informati...
Autores principales: | Beck, Alain, Nowak, Christine, Meshulam, Deborah, Reynolds, Kristina, Chen, David, Pacardo, Dennis B., Nicholls, Samantha B., Carven, Gregory J., Gu, Zhenyu, Fang, Jing, Wang, Dongdong, Katiyar, Amit, Xiang, Tao, Liu, Hongcheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703962/ https://www.ncbi.nlm.nih.gov/pubmed/36412839 http://dx.doi.org/10.3390/antib11040073 |
Ejemplares similares
-
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
por: Dagbay, Kevin B., et al.
Publicado: (2020) -
Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies
por: Beck, Alain, et al.
Publicado: (2019) -
Generation and diversification of recombinant monoclonal antibodies
por: DeLuca, Keith F, et al.
Publicado: (2021) -
Open-source recombinant monoclonal secondary nanobodies
por: Ewers, Helge
Publicado: (2018) -
In-Depth Method for the Characterization of Glycosylation
in Manufactured Recombinant Monoclonal Antibody Drugs
por: Song, Ting, et al.
Publicado: (2014)